SNDL
SNDLANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
SNDL has liquidity, buyback capacity, and a diversified liquor, cannabis, and investment platform. Successful cost and commercial initiatives, improved cannabis conditions in the second half of 2026, or investment monetization could improve per-share value [#PR-2026-04-29].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Execution risk on cost, commercial, and margin-improvement initiatives.
Momentum
99
Value
67
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.40 · Bull $1.75 · Bear $0.95
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $4.15
Why
Momentum99 · Δ7d -
Value67 · Δ7d -0.0
Sentiment53 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
99
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
67
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.5
Sentiment
53
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 99.0 / Value 66.8 / Sentiment 53.3
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$333.18M
Beta
0.82
Shares Out
260.3M
P/E (TTM) · Derived
-29.3
P/S (TTM)
0.64
P/FCF (TTM)
10.53
Rev YoY
+0.0%
EPS YoY
-30.1%
Gross Margin
+21.7%
Op Margin
-9.7%
Net Debt
-$75.11M
Current Ratio
4.84
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology